Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
0.6909
-0.1492 (-17.76%)
Jun 4, 2025, 1:41 PM - Market open
Moleculin Biotech Stock Forecast
MBRX's stock price has decreased by -85.66% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Moleculin Biotech stock ranges from a low of $4.00 to a high of $8.00. The average analyst price target of $6.00 forecasts a 768.43% increase in the stock price over the next year.
Price Target: $6.00 (+768.43%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 25, 2025.
Analyst Ratings
The average analyst rating for Moleculin Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $4 | Hold → Strong Buy | Upgrades | $4 | +478.95% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +1,057.91% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +1,057.91% | Mar 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +1,057.91% | Mar 3, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $20 → $8 | Strong Buy | Maintains | $20 → $8 | +1,057.91% | Nov 12, 2024 |
Financial Forecast
Revenue This Year
n/a
from 74.14M
Revenue Next Year
n/a
EPS This Year
-1.71
from -6.32
EPS Next Year
-1.51
from -1.71
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.43 | -1.54 | -1.38 | ||
| Avg | -1.71 | -1.51 | -1.40 | ||
| Low | -1.98 | -1.47 | -1.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.